Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment (Q24803596)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment	scientific article

Statements

scholarly article

0 references

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Allan E Rodriguez

4

object named as

Allan Rodriguez

0 references

author name string

Philip H Keiser

1

0 references

Michael G Sension

2

0 references

Edwin DeJesus

3

0 references

Jeffrey F Olliffe

5

0 references

Vanessa C Williams

6

0 references

John H Wakeford

7

0 references

Jerry W Snidow

8

0 references

Anne D Shachoy-Clark

9

0 references

Julie W Fleming

10

0 references

Gary E Pakes

11

0 references

Jaime E Hernandez

12

0 references

language of work or name

0 references

publication date

12 January 2005

0 references

BMC Infectious Diseases

0 references

5

0 references

1

0 references

2

0 references

https://scigraph.springernature.com/pub.10.1186/1471-2334-5-2

0 references

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

7 April 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

7 April 2017

Evaluation of methods for the measurement of low-density lipoprotein cholesterol.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

7 April 2017

Impact of nevirapine on lipid metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Switching effective antiretroviral therapy: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Cardiovascular risk associated with HIV therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Switch studies: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Abacavir: a review of its clinical potential in patients with HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

28 September 2017

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

30 May 2018

Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

30 May 2018

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

30 May 2018

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548524

30 May 2018

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Metabolic basis of HIV-lipodystrophy syndrome

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Abacavir hypersensitivity reaction

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-2

21 January 2018

Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15647105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15647105

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-5-2

0 references

Dimensions Publication ID

0 references

release_u3hoe4mxwnakzakmknu2enxg6a

1 reference

https://api.fatcat.wiki/v0/release/u3hoe4mxwnakzakmknu2enxg6a

24 November 2022

based on heuristic

mapped directly with Wikidata item

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24803596&oldid=1964014080"